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Both Raloxifene and Estrogen Reduce Major Cardiovascular
Risk Factors in Healthy Postmenopausal Women
A 2-Year, Placebo-Controlled Study
Gerdien W. de Valk-de Roo, Coen D.A. Stehouwer, Piet Meijer, Velja Mijatovic, Cornelis Kluft,
Peter Kenemans, Fredric Cohen, Steven Watts, Coen Netelenbos
Abstract—Currently raloxifene, a selective estrogen receptor modulator, is being investigated as a potential alternative for
postmenopausal hormone replacement to prevent osteoporosis and cardiovascular disease. We compared the 2-year
effects of raloxifene on a wide range of cardiovascular risk factors with those of placebo and conjugated equine
estrogens (CEEs). Analyses were based on 56 hysterectomized but otherwise healthy postmenopausal women aged
54.863.5 (mean6SD) years who entered this double-blind study and who were randomly assigned to raloxifene
hydrochloride 60 mg/d (n515) or 150 mg/d (n513), placebo (n513), or CEEs 0.625 mg/d (n515). At baseline and after
6, 12, and 24 months of treatment, we assessed serum lipids, blood pressure, glucose metabolism, C-reactive protein,
and various hemostatic parameters. Compared with placebo, both raloxifene and CEEs lowered the level of low density
lipoprotein cholesterol by 0.53 to 0.79 mmol/L (all P,0.04) and lowered, at 24 months, the level of fibrinogen by 0.71
to 0.86 g/L (all P,0.05). The effects of raloxifene and CEEs did not differ significantly. In contrast to raloxifene, from
6 months on CEEs increased high density lipoprotein cholesterol by 0.25 to 0.29 mmol/L and reduced plasminogen
activator inhibitor-1 antigen by 30.6 to 48.6 ng/mL (all P,0.02 versus both placebo and raloxifene). CEEs transiently
increased C-reactive protein by 1.0 mg/L at 6 months (P,0.05 versus placebo) and prothrombin-derived fragment F112
by 0.79 nmol/L at 12 months (P,0.001 versus placebo). Finally, from 12 months on, CEEs increased triglycerides by
0.33 to 0.56 mmol/L (all P,0.05 versus both placebo and raloxifene). Our findings suggest that in healthy
postmenopausal women, raloxifene and estrogen monotherapy have similar beneficial effects on low density lipoprotein
cholesterol and fibrinogen levels. These treatments differ, however, in their effects on high density lipoprotein
cholesterol, triglycerides, and plasminogen activator inhibitor-1 and possibly in their effects on prothrombin fragment
F112 and C-reactive protein. (Arterioscler Thromb Vasc Biol. 1999;19:2993-3000.)
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Observational studies among postmenopausal womenhave found that the use of estrogens with or without
progestogens is associated with a reduction of the risk of
osteoporosis,1,2 cardiovascular disease,3–5 and overall mortal-
ity.6 The results of the recently published HERS study (Heart
Estrogen-progestin Replacement Study), the only randomized
trial so far, were therefore disappointing, in that it showed no
beneficial effect of postmenopausal hormone replacement
therapy on cardiovascular morbidity and/or mortality.7 It did
concern, however, a secondary prevention study of conju-
gated equine estrogens (CEEs) continuously combined with
medroxyprogesterone acetate. Results of that study may
therefore not be extrapolated to healthy postmenopausal
women nor to other regimens of hormone replacement
therapy. Disadvantages of the prolonged use of hormone
replacement with estrogens and progestogens include an
increase in the risk of breast cancer,8,9 a possible increase in
the risk of endometrial carcinoma,10 and the recurrence of
vaginal bleeding.
To increase the benefit-risk ratio of hormone replacement
therapy, so-called designer estrogens are being developed:
nonhormonal agents that bind with high affinity to the
estrogen receptor and exhibit tissue-specific, estrogen-agonist
or -antagonist effects. The tissue specificity of designer
estrogens may be related to the existence of (at least) 2
different isoforms of the estrogen receptor with distinct
signaling properties, depending on the ligand and the re-
sponse element.11,12 Raloxifene, a nonsteroidal benzothio-
phene derivative, is a designer estrogen of which relatively
much experience has been gained. It possesses beneficial
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estrogen-agonist effects on bone13 and cardiovascular risk
factors13,14 but estrogen-antagonist effects on the endometri-
um13 and breast tissue.15 However, in ovariectomized mon-
keys fed an atherogenic diet, long-term treatment with ralox-
ifene in contrast to CEEs did not reduce coronary artery
plaque size.16 The long-term effects of raloxifene on cardio-
vascular risk factors have not been extensively investigated.
Therefore, we compared the effects of raloxifene on serum
lipids, blood pressure, glucose metabolism, and hemostatic
cardiovascular risk factors with those of placebo and CEEs in
a group of hysterectomized but otherwise healthy postmeno-
pausal women in a double-blind, randomized study of 2
years’ duration.
Methods
Subjects
Sixty postmenopausal, hysterectomized but otherwise healthy
women (mean6SD age 54.863.5 years) were included in the study.
Hysterectomy had been performed because of a benign endometrial
abnormality (n550), uterine prolapse (n58), and/or a benign ovarian
abnormality (n55). Postmenopausal status was defined as a serum
estradiol level #73 pmol/L and a follicle-stimulating hormone level
$40 IU/L. Exclusion criteria were a history of breast carcinoma
and/or recent thromboembolism; evidence of liver disease and/or
renal dysfunction; use of lipid-lowering drugs and/or anticonvul-
sives; and use of sex steroids and/or corticosteroids more recently
than 6 months before the start of the study. Hypertension was not an
exclusion criterion. Four participants dropped out of the study before
the first postbaseline visit. Reasons for withdrawal were incorrect
inclusion (placebo group), nausea (raloxifene 150-mg group), per-
sonal conflict (placebo group), and death due to a traffic accident
(raloxifene 150-mg group). These subjects were excluded from the
analyses. Analyses in this report are therefore based on 56 women
randomly assigned to 1 of 4 treatment groups: placebo (n513), CEEs
0.625 mg/d (n515), and raloxifene hydrochloride 60 mg/d (n515)
and 150 mg/d (n513). All women received 500 mg of elemental
calcium per day. To monitor compliance, at each visit the subjects
returned the unused medication, which was then counted. If a subject
had missed .30% of the study medication during 2 separate time
periods, she was regarded as severely noncompliant. The study was
conducted on an outpatient basis according to the principles of the
Declaration of Helsinki and was approved by the medical ethics
committee of the Academic Hospital Vrije Universiteit of Amster-
dam. Informed consent was obtained from all volunteers after oral
and written information was supplied.
General Procedures
At baseline and at 12-month intervals, smoking status (yes or no),
body mass index (weight/height2), and blood pressure were assessed.
Blood pressure (mean of 4 readings) was measured on the left arm
after 10 minutes of rest by using an automated device (BP-8800,
Colin). Hypertension was defined as a systolic blood pressure
$160 mm Hg and/or a diastolic blood pressure $95 mm Hg and/or
the use of antihypertensive drugs. At baseline and after 6, 12, and 24
months of treatment, blood samples were collected between 8:30 and
11:30 AM after an overnight fast. Circulating levels of insulin, all
markers of coagulation and fibrinolysis, and C-reactive protein
(CRP) were assayed at the end of the study in a single run. A
carefully standardized procedure17 was applied for samples to be
used for determination of markers of coagulation and fibrinolysis.
Laboratory Variables
At baseline, we measured serum levels of estradiol (radioimmuno-
assay; Double Antibody, DPC) and of follicle-stimulating hormone
(microparticle enzyme immune assay; IMX, Abbott Laboratories).
TABLE 1. General Characteristics at Baseline
Total
Placebo
(n515)
Ral 60 mg/d
(n515)
Ral 150 mg/d
(n515)
CEEs 0.625 mg/d
(n515)
Age, y 54.863.5 54.964.5 54.063.5 54.662.8 55.763.2
Estradiol, pmol/L 11 (9; 14) 12 (7; 20) 11 (7; 19) 15 (8; 27) 8 (6; 11)
FSH, U/L 81623 91626 79619 67611 86628
BMI, kg/m2 26.663.5 27.064.2 26.564.2 26.262.3 26.863.4
Smoking, % 23 15 13 46 20
SBP, mm Hg 125614 127616 121611 125615 127613
Hypertension,* % 11 8 13 15 7
TC, mmol/L 6.461.1 6.461.3 6.661.2 6.361.0 6.361.1
HDL-C, mmol/L 1.660.4 1.660.5 1.760.3 1.560.4 1.560.3
LDL-C, mmol/L 4.361.0 4.461.1 4.561.1 4.260.8 4.361.1
TG, mmol/L 1.0 (0.8; 1.1) 1.0 (0.8; 1.2) 0.9 (0.8; 1.1) 1.2 (1.0; 1.4) 0.8 (0.5; 1.2)
Glucose, mmol/L 5.060.6 4.860.5 5.060.3 5.461.0 5.160.5
Insulin, pmol/L 48 (42; 54) 42 (31; 58) 46 (36; 59) 53 (43; 65) 50 (43; 59)
CRP, mg/L 1.2 (0.9; 1.6) 1.2 (0.8; 1.8) 1.1 (0.6; 2.1) 1.1 (0.7; 1.7) 1.6 (1.0; 2.5)
Fibrinogen, g/L 3.660.8 3.660.6 3.660.9 3.360.5 3.860.8
Factor VII antigen, % 89613 89610 91614 89617 88610
F112, nmol/L 1.360.4 1.260.4 1.360.5 1.460.4 1.460.4
TAT, mg/L 3.1 (2.6; 3.7) 3.6 (2.5; 5.0) 3.4 (2.2; 5.3) 2.5 (1.9; 3.3) 2.9 (2.1; 4.1)
tPA, mg/L 7.962.6 6.962.4 7.962.2 8.262.2 8.463.4
PAI-1, mg/L 52 (43; 63) 40 (26; 63) 56 (40; 78) 56 (44; 72) 58 (38; 90)
PAP, mg/L 4466139 4516177 4476114 4256147 4606130
D-dimer, mg/L 22 (17; 28) 26 (17; 40) 16 (11; 25) 18 (11; 31) 30 (18; 47)
Ral indicates raloxifene; FSH, follicle-stimulating hormone; BMI, body mass index; SBP, systolic blood pressure; and TAT, thrombin-
antithrombin complexes. Values are mean6SD or, for nonnormally distributed variables, the geometric mean with its 95% CI.
*As defined by World Health Organization criteria.
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At baseline and after 6, 12, and 24 months of treatment, we
measured serum total cholesterol (TC), HDL cholesterol (HDL-C),
and triglycerides (TGs; all with enzymatic methods from Boehringer
Mannheim). LDL cholesterol (LDL-C) was calculated by the Friede-
wald formula. Serum insulin was measured by an immunoradiomet-
ric assay (Biosource Diagnostics; intra-assay CV 5%). Coagulation
activity was assessed by measuring fibrinogen (thrombin time
method according to Clauss; STA fibrinogen kit, Boehringer Mann-
heim), factor VII antigen (enzyme immunoassay; Asserchrom, Di-
agnostica Stago), the prothrombin-derived fragment 112 (F112),
and thrombin-antithrombin complexes (both by enzyme immunoas-
say; Enzygnost, Behringwerke, with detection limits of 0.02 nmol/L
and 0.5 mg/L, respectively). Fibrinolytic activity was determined by
measuring tissue-type plasminogen activator antigen (tPA; ELISA
Imulyse t-PA, Biopool, with a detection limit of 1.5 mg/L), plasmin-
ogen activator inhibitor-1 antigen (PAI-1 enzyme immunoassay;
Innotest PAI-1, Innogenetics, with a detection limit of 2.5 mg/L), and
plasmin-antiplasmin complexes (PAP) and D-dimer (both by en-
zyme immunoassay; Enzygnost, Behringwerke, with a detection
limit of 10 and 0.5 mg/L, respectively). Intra-assay CVs were all
,10% except for tPA, for which they were ,12%. Because
inflammation may play a role in the pathogenesis of atherothrom-
botic disease,18 we also measured levels of CRP with a sensitive
(detection limit of 0.01 mg/L) in-house enzyme immunoassay with
antibodies supplied by Dako. The intra-assay CVs were ,10%.
Statistical Analyses
The statistician did not have any contact with the participants, and
the physicians did not know the randomization codes. Data are given
as mean6SD. For variables for which the residuals of the fitted
least-squares model were not normally distributed, logarithmic
transformation gave approximately symmetrical distributions that
were used for all statistical analyses described below. For these
variables, geometric means with their 95% CIs are presented. At
baseline, we assessed the general characteristics for the 4 different
treatment groups and compared these by either 1-way ANOVA or by
Fisher’s exact test. Additionally, at 12 and 24 months, the prevalence
of hypertension in each of the treatment groups was assessed and
compared by Fisher’s exact test. Missing values were replaced by
carrying forward the last available postbaseline value. Analyses of
particular importance were those comparing any raloxifene group to
either the placebo group or the CEE group. Pairwise comparisons
were carried out within the framework of the ANOVA by using the
treatment group least-square means (LSMEANS) and the pooled
variance of the LSMEANS; pairwise differences between any 2
treatment groups were established by contrasting the differences in
the treatment LSMEANS by using the pooled variance. Tests of
within-group changes versus baseline were carried out with Stu-
dent’s t tests. Any pairwise differences were examined for signifi-
cance only after an overall treatment group difference had been
established. Overall changes from baseline were evaluated by using
repeated-measures ANOVA. This was accomplished by using the
Statistical Analysis System MIXED procedure, in which the model
included effects for therapy, visit, and therapy-by-visit interaction.
These analyses assumed an autoregressive covariance structure.
Finally, Pearson correlations were used to assess associations be-
tween markers of fibrinolysis. Statistical tests resulting in P,0.05
were judged to be significant. All analyses were performed with SAS
version 6.08 running under the MVS operating system.
Results
Table 1 shows the baseline values of all variables measured
for all women included in the study. At baseline there were no
significant differences among the 4 groups except for the
mean follicle-stimulating hormone level, which was '25%
lower in the raloxifene 150-mg group than in the placebo and
CEE groups. Fifty-two women completed the 2-year follow-
up. Four women withdrew before the first postbaseline visit
and 4 after this visit. For the latter 4, who remained in the
analyses, the reasons for leaving the study were development
of a deep venous thrombosis (after 6.5 months; raloxifene
60-mg group), carcinoma of the bladder (after 9.5 months;
CEE group), and personal conflict (after 9.5 and 12.1 months;
raloxifene 60-mg and placebo groups). There was no severe
noncompliance, as defined in Methods, in any of the treat-
ment groups.
Lipid Levels
At 24 months, raloxifene at 60 and 150 mg/d decreased the
mean serum TC by 0.67 and 0.59 mmol/L, respectively
(P,0.03 versus both placebo and CEE groups; Table 2).
CEEs did not affect the serum TC. For LDL-C, the overall
change from baseline in the placebo group differed signifi-
cantly from the overall change from baseline in both the CEE
TABLE 2. Change From Baseline: Active Treatment Versus Placebo—Lipids
Months Ral 60 mg/d P Ral 150 mg/d P CEEs 0.625 mg/d P
TC, mmol/L 6 20.56 (21.05,20.08) 20.30 (20.80, 0.20) 20.26 (20.74, 0.22)
12 20.52 (20.98, 20.07) 20.59 (21.05, 20.12) 20.24 (20.69, 0.21)
24 20.67 (21.16, 20.18) † § 20.59 (21.10, 20.09) *§ 20.03 (20.52, 0.46)
LDL-C, mmol/L 6 20.61 (21.06, 20.16) * 20.52 (20.99, 20.06) * 20.67 (21.12, 20.23) †
12 20.54 (20.95, 20.13) * 20.65 (21.08, 20.23) † 20.65 (21.06, 20.23) †
24 20.76 (21.18, 20.34) † 20.79 (21.23, 20.36) † 20.53 (20.95, 20.11) *
HDL-C, mmol/L 6 0.00 (20.13, 0.14) ¶ 0.12 (20.01, 0.26) § 0.29 (0.16, 0.42) †
12 20.01 (20.15, 0.13) ¶ 0.04 (20.11, 0.18) ¶ 0.26 (0.12, 0.39) †
24 0.06 (20.09, 0.21) § 0.06 (20.09, 0.22) § 0.25 (0.10, 0.40) †
TG, mmol/L\ 6 0.09 (20.31, 0.49) 0.23 (20.18, 0.64) 0.27 (20.13, 0.67)
12 0.05 (20.27, 0.38) § 0.07 (20.27, 0.41) § 0.33 (0.00, 0.66) *
24 0.07 (20.29, 0.42) ¶ 0.30 (20.07, 0.66) § 0.56 (0.21, 0.91) †
Ral indicates raloxifene. CEEs indicates conjugated equine estrogens. Values are mean changes (with 95% CIs) from baseline in
the active-treatment groups relative to corresponding mean changes from baseline in the placebo group. Because simple
back-transformation of a difference between 2 values for the same measure at 2 different times is not allowed, changes versus
baseline are based on actual values.
*P,0.05, †P,0.01, ‡P,0.001, significantly different from baseline.
§P,0.05, ¶P,0.01, #P,0.001, significantly different from CEEs.
\Logarithmically transformed values.
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and the raloxifene groups (P50.002; the Figure). From 6
months onward, both raloxifene and CEEs decreased the
mean LDL-C to a similar extent (by 0.52 to 0.79 mmol/L,
P,0.05 versus placebo). Compared with placebo, raloxifene
did not change HDL-C, whereas CEEs increased the mean
HDL-C (P,0.02 versus both placebo and raloxifene). Com-
pared with placebo, TG serum levels were not affected by
raloxifene; in contrast, from 12 months on, TG levels were
raised by CEEs (P,0.05 versus both placebo and raloxifene).
Blood Pressure
Compared with placebo, neither raloxifene nor CEEs signif-
icantly affected systolic or diastolic blood pressure (data not
shown). Two participants started antihypertensive therapy
during the study. One participant stopped her antihyperten-
sive medication. At none of the time points measured,
however, did the prevalence of hypertension differ signifi-
cantly among the groups.
Biochemical Markers of Coagulation
The overall change in fibrinogen from baseline in the placebo
group tended to be different from the overall change from
baseline in both the CEE and raloxifene groups (P50.06; the
Figure). Compared with placebo, at 24 months raloxifene and
CEEs decreased the mean fibrinogen level by 0.71 to 0.86 g/L
(P,0.04; Table 3). At none of the follow-up measurements
was the effect between raloxifene and CEEs significantly
different. Compared with placebo, neither raloxifene nor
CEEs affected factor VII antigen or thrombin-antithrombin
complex. Compared with placebo, raloxifene did not signif-
icantly affect the mean F112; at 12 months, CEEs transiently
increased the mean F112 by 0.79 nmol/L (P,0.001).
Biochemical Markers of Fibrinolysis
In the placebo group, an increase in PAI-1 (by 8.4, 13, and 5.3
mg/L, respectively; all P,0.08; the Figure) and a decrease in
the tPA–PAI-1 ratio (all P,0.05; data not shown) were seen
at all 3 time points [Table 4]. Compared with placebo, the
levels of tPA and PAI-1 did not change significantly with
raloxifene therapy, nor did the tPA–PAI-1 ratio. In contrast,
compared with placebo, at 6 and 24 months CEEs reduced the
mean tPA level by 2.04 and 2.25 mg/L, respectively (P,0.05
versus both placebo and raloxifene). From 6 months on,
CEEs decreased the mean PAI-1 level by 30.6 to 48.6 mg/L
(P,0.02 versus both placebo and raloxifene) as well as the
mean tPA–PAI-1 ratio. The increase in the tPA–PAI-1 ratio
was significant versus placebo at 6 and 12 months
(P,0.002). The overall change in PAI-1 from baseline in the
CEE group differed significantly from the overall change
from baseline in the other groups (P,0.001, the Figure). PAP
as well as D-dimer showed wide scatter and did not change
significantly in any of the groups. There was, however, at all
time points an inverse correlation between PAI-1 and PAP
(r520.38 to 20.62; all P,0.005) and a positive correlation
between the tPA–PAI-1 ratio and PAP (r50.48 to 0.68;
P,0.001) in the entire group. Furthermore, any change
versus baseline in PAI-1 was negatively associated with any
change versus baseline in PAP (r520.42 to 20.62;
Change from baseline for LDL-C, fibrinogen, PAI-1, and CRP.
Values are either mean6SD (upper panels) or medians (lower
panels). For PAI-1 and CRP, significance is based on logarithmi-
cally transformed ANOVA for repeated measurements over time.
F indicates placebo; E, raloxifene 60 mg; □, raloxifene 150 mg;
n, CEEs 0.625 mg. #P50.06; upP50.07; **P,0.01; ***P,0.001.
TABLE 3. Change From Baseline: Active Treatment Versus Placebo—Coagulation Markers
Months Ral 60 mg/d P Ral 150 mg/d P CEEs 0.625 mg/d P
Fibrinogen, g/L 6 20.41 (20.88, 0.06) 20.22 (20.71, 0.27) 20.20 (20.68, 0.28)
12 20.70 (21.29, 20.12) 20.63 (21.24, 20.03) 20.57 (21.15, 0.02)
24 20.86 (21.46, 20.26) † 20.71 (21.33, 20.08) * 20.77 (21.37, 20.16) *
Factor VII antigen, % 6 22.1 (29.9, 5.6) 23.2 (211.1, 4.7) 3.2 (24.5, 11.0)
12 2.4 (26.3, 11.1) 3.0 (25.8, 11.8) 4.6 (24.0, 13.1)
24 3.2 (27.4, 13.7) 6.6 (24.2, 17.4) 8.6 (21.8, 19.0)
F112, nmol/L 6 0.07 (20.25, 0.40) 0.21 (20.12, 0.55) 0.35 (0.02, 0.67)
12 0.04 (20.38, 0.47) ‡ 0.36 (20.08, 0.80) 0.79 (0.36, 1.22) ‡
24 20.10 (20.54, 0.33) 0.05 (20.40, 0.50) 0.05 (20.38, 0.48)
TAT, mg/L\ 6 22.0 (26.7, 2.7) 21.7 (26.5, 3.2) 23.1 (27.9, 1.7)
12 22.0 (27.8, 3.8) 5.8 (20.2, 11.9) 20.1 (25.9, 5.7)
24 24.6 (210.1, 0.9) 23.6 (29.3, 2.0) 24.2 (29.8, 1.3)
See the footnote to Table 2 for an explanation of symbols and abbreviations. TAT indicates thrombin-antithrombin complex.
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P,0.002), and any change in the tPA–PAI-1 ratio was
positively associated with any change in PAP (r50.51 to
0.55; P,0.001). No consistent association existed between
the level of PAI-1 or the tPA–PAI-1 ratio and D-dimer.
CRP and Carbohydrate Metabolism
Compared with placebo, raloxifene did not change CRP
levels; at 6 months of treatment, however, CEE induced a
transient increase (P50.006, Table 5). The overall increase
from baseline in the CEE group differed marginally from the
overall change from baseline in both the placebo and ralox-
ifene treatment groups (P50.07; the Figure). Compared with
placebo, neither raloxifene nor CEEs showed a significant
effect on fasting levels of glucose and/or insulin.
Additional Analyses
Adjustment for smoking habits by ANCOVA did not mate-
rially affect the results (data not shown).
Discussion
There were 2 main findings. First, both raloxifene and CEEs
lowered LDL-C and fibrinogen levels. Second, CEEs, but not
raloxifene, decreased PAI-1 and increased HDL-C, TG,
F112, and CRP levels. These results suggest that both CEEs
and raloxifene are associated with a sustained improvement
of the cardiovascular risk profile but that there are important
differences between these agents.
Comparable Effects of Raloxifene and CEEs
The sustained decrease in LDL-C and fibrinogen levels
after both CEE and raloxifene treatment may be considered
beneficial from the cardiovascular point of view.19,20
LDL-C may promote cardiovascular disease by the induc-
tion of endothelial dysfunction21 and fibrinogen by its
effects on hemostasis, blood rheology, platelet aggrega-
tion, and endothelial function.20 The effects of CEEs22,23
and raloxifene13,14 on LDL-C levels that we found are in
line with earlier studies. Similarly, previous studies have
shown that estrogen replacement was associated with a
diminished increase or a slight decrease in fibrinogen
levels over time23,24 and that treatment with tamoxifen25
and raloxifene14 decreased fibrinogen levels. Our study
confirms and extends these data14 by showing that the
effects of raloxifene increase with time. It is thought that
estrogens and, presumably, raloxifene reduce LDL-C lev-
els by enhancing LDL clearance as a result of hepatic LDL
receptor induction.26,27 How estrogens and selective estro-
TABLE 4. Change From Baseline: Active Treatment Versus Placebo—Fibrinolysis Markers
Months Ral 60 mg/d P Ral 150 mg/d P CEEs 0.625 mg/d P
tPA, mg/L 6 20.70 (21.73, 0.32) § 20.47 (21.53, 0.59) ¶ 22.04 (23.09,21.00) ‡
12 0.42 (21.02, 1.87) 20.38 (21.88, 1.11) 21.30 (22.74, 0.15)
24 20.55 (22.20, 1.09) § 0.15 (21.56, 1.85) ¶ 22.25 (23.90, 20.61) †
tPA–PAI-1 ratio 6 0.04 (20.01, 0.09) 0.03 (20.02, 0.08) § 0.09 (0.04, 0.14) †
12 0.05 (0.00, 0.11) § 0.04 (20.02, 0.10) § 0.11 (0.06, 0.17) ‡
24 0.03 (20.02, 0.09) 0.02 (20.03, 0.09) 0.08 (0.02, 0.13)
PAI-1, mg/L\ 6 214.1 (247.6, 19.4) § 20.3 (234.9, 34.4) ¶ 248.6 (282.6, 214.6) ‡
12 25.4 (249.7, 38.9) ¶ 2.8 (243.0, 48.7) ¶ 248.4 (292.7, 24.1) ‡
24 26.3 (234.0, 21.4) § 15.8 (212.9, 44.4) ¶ 230.6 (258.3, 22.9) ‡
PAP, mg/L 6 23.8 (289.3, 81.8) 215.1 (2103.6, 73.5) 50.0 (237.0, 136.9)
12 253.8 (2146.3, 38.7) 229.4 (2125.1, 66.4) 15.2 (277.3, 107.7)
24 283.2 (2192.3, 25.8) 279.9 (2192.8, 33.1) 252.5 (2161.7, 56.7)
D-dimer, mg/L\ 6 13 (236, 61) 1 (249, 51) 211 (260, 38)
12 18 (235, 71) 19 (235, 74) 214 (267, 39)
24 8 (245, 62) 21 (257, 55) 220 (273, 34)
See the footnote to Table 2 for an explanation of symbols and abbreviations.
TABLE 5. Changes From Baseline: Active Treatment Versus Placebo—CRP and Carbohydrate Metabolism
Months Ral 60 mg/d P Ral 150 mg/d P CEEs 0.625 mg/d P
CRP, mg/L\ 6 21.5 (24.1, 1.1) § 0.8 (21.9, 3.6) 1.0 (21.6, 3.7) †
12 23.0 (26.5, 0.5) 21.5 (25.1, 2.1) 0.4 (23.0, 3.9)
24 23.1 (26.2, 0.04) 21.4 (24.6, 1.9) 21.3 (24.4, 1.9)
Glucose, mmol/L 6 20.01 (20.3, 0.3) 20.1 (20.4, 0.2) 20.2 (20.5, 0.1)
12 20.1 (20.4, 0.2) 20.3 (20.6,0.0) 20.1 (20.5, 0.2)
24 20.1 (20.4,0.2) 20.1 (20.4,0.2) 20.2 (20.5, 0.1)
Insulin, pmol/L\ 6 29 (224, 6) 25 (220, 10) 27 (222, 7)
12 2 (214, 18) 1 (216, 18) 24 (220, 12)
24 21 (220, 19) 7 (214, 27) 23 (223, 17)
See the footnote to Table 2 for an explanation of symbols and abbreviations.
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gen receptor modulators influence fibrinogen levels is not
known.
Different Effects of Raloxifene and CEEs
In contrast to CEEs, raloxifene did not affect the levels of
HDL-C, TG, PAI-1, tPA, F112, and/or CRP. Observational
studies have shown that cardiovascular prognosis is adversely
affected by a decrease in HDL-C28,29 and by an increase in
TG,28,30 PAI-1,31–33 tPA,33,34 and CRP.35–37
It is therefore reasonable to assume that the increase in
HDL-C observed with CEEs, which is thought to be mediated
at least partly by an effect on hepatic lipase,38,39 represents a
favorable change. The CEE-associated increase in TG may be
innocuous, as this likely reflects enhanced synthesis of large,
nonatherogenic, VLDL particles.22 Our results are in agree-
ment with earlier reports on the effects of estrogen22,23 and
raloxifene13,14 on HDL-C and TG. The mechanistic basis of
the difference between CEEs and raloxifene, however, is not
known.
It is less clear how the effects of CEEs on the markers of
hemostasis, PAI-1, tPA, and F112, should be interpreted.
The CEE-induced decrease in both PAI-1 and tPA could be
regarded as beneficial, because PAI-1 is an essential antago-
nist of fibrinolysis and because the antigen levels of tPA
primarily reflect the levels of circulating tPA–PAI-1 com-
plexes. Although the level of PAP, a marker of fibrinolysis
activation , and of D-dimer, a degradation product of cross-
linked fibrin, did not increase significantly, for the whole
group any decrease in PAI-1 was significantly associated
with an increase in PAP (r520.42 to 20.62; P,0.002), and
any increase in the tPA–PAI ratio was significantly associ-
ated with an increase in PAP (r50.51 to 0.55; P,0.001). Our
data concerning the effects of CEEs on fibrinolysis are
consistent with previous experience.40–45 None of these
previous studies, however, had a duration of .1 year, nor did
they include a placebo group. Oral estrogens may decrease
both PAI-1 and tPA levels by affecting adipose tissue
metabolism46 or by the upregulation of the hepatic clearance
of tPA–PAI-1 complexes.47,48 Our study suggests no impor-
tant influence of raloxifene on fibrinolysis.
CEEs, but not raloxifene, transiently increased levels of
F112, a marker of activated coagulation, which is in accor-
dance with previous experience in short-term trials.14,43,45,49
Raloxifene may thus have some advantage over CEEs in this
respect. The temporary character of the F112 increase is
reminiscent of the results of the HERS study, which, in the
first year of hormone use, showed more coronary events in
the hormone group than in the placebo group.7
It must be noted that part of the changes induced by CEEs
may result from the hepatic first-pass effect of oral estrogen.
With respect to some cardiovascular parameters, transdermal
estrogen administration may have effects that are similar to
those of oral raloxifene. For example, transdermal estrogen
does not affect circulating levels of TG,22 HDL-C,50 PAI-
1,40,42,45 and F112.45 This may have implications for the
choice of prescription: transdermal estrogen or raloxifene, for
example, may be preferred in subjects with hypertriglyceri-
demia. So far, however, the implications with regard to
clinical events of the differential effects of oral versus
transdermal estrogen are unclear.
In contrast to raloxifene, CEEs transiently increased levels
of CRP. There appear to be no previous published data on this
issue. Even slightly increased CRP levels are a strong
predictor of an adverse cardiovascular prognosis in both
men35,36 and women.37 The interpretation of these findings is
unclear and includes at least 2 concepts: that elevated CRP
levels reflect the hepatic response to inflammation in the
vascular wall,36 an important component of atherosclerosis,
and that CRP itself activates processes that lead to vascular
damage.51 The contrasting effects of CEEs on fibrinogen
(decrease) and CRP (increase) argue somewhat against a
CEE-associated increase in inflammatory activity but do not
exclude it. This issue requires further investigation.
No Effect of Raloxifene and CEEs
Finally, we assessed the effects of CEEs and raloxifene on
factor VII antigen, glucose, and insulin levels and on blood
pressure and found no differences compared with placebo.
This conclusion is limited, however, by the fact that we used
relatively insensitive methods to assess these variables.
Study Limitations and Conclusions
We included only hysterectomized women, which enabled us
to study the effects of conjugated estrogen without the
addition of a progestogen and to compare the effects of
raloxifene with estrogen-only therapy. This study had some
limitations. First, it was relatively small, and we therefore
cannot exclude relatively small treatment effects. Second,
besides the effects described in this article, estrogen replace-
ment and potentially raloxifene may have important direct (ie,
LDL-C–independent) effects on endothelium-dependent and
-independent vascular function.52–55
In conclusion, this study, which comprised hysterecto-
mized but otherwise healthy postmenopausal women aged 45
to 60 years, clearly shows that with respect to cardiovascular
risk factors, raloxifene behaves as a partial estrogen agonist.
Like CEEs, raloxifene showed a favorable influence on 2
generally recognized risk markers of cardiovascular disease,
ie, LDL-C and fibrinogen levels. Unlike CEEs, however, it
neither increased HDL-C nor decreased PAI-1 levels. Both
raloxifene and CEEs express beneficial effects on bone
mineral density; in contrast to CEEs, raloxifene seems not to
influence the endometrium and breast tissue. In healthy
postmenopausal women, raloxifene may thus be an attractive
alternative for estrogen replacement in the prevention of
cardiovascular disease and osteoporosis. Further prospective,
randomized trials with clinical end points, however, are
necessary to prove that CEEs and raloxifene improve cardio-
vascular prognosis in postmenopausal women.
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